MARKET

PPCB

PPCB

Propanc Bio
NASDAQ
0.6280
-0.0230
-3.53%
After Hours: 0.6104 -0.0176 -2.80% 19:48 09/23 EDT
OPEN
0.6392
PREV CLOSE
0.6510
HIGH
0.6525
LOW
0.6004
VOLUME
194.13K
TURNOVER
--
52 WEEK HIGH
53.40
52 WEEK LOW
0.5950
MARKET CAP
2.20M
P/E (TTM)
-0.0189
1D
5D
1M
3M
1Y
5Y
1D
Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015
TipRanks · 1d ago
Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
Benzinga · 1d ago
Weekly Report: what happened at PPCB last week (0914-0918)?
Weekly Report · 2d ago
Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015
Benzinga · 09/16 12:33
Weekly Report: what happened at PPCB last week (0907-0911)?
Weekly Report · 09/14 10:26
Propanc Biopharma to commence first-in-human study of PRP in February
TipRanks · 09/09 13:05
Weekly Report: what happened at PPCB last week (0831-0904)?
Weekly Report · 09/07 10:19
Weekly Report: what happened at PPCB last week (0824-0828)?
Weekly Report · 08/31 10:27
More
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Webull offers Propanc Biopharma Inc stock information, including NASDAQ: PPCB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPCB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PPCB stock methods without spending real money on the virtual paper trading platform.